By joining the group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD, RetinAI hopes to forge a global retinal imaging initiative targeting research in the disease.
RetinAI Medical AG announced it is joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers and industry partners working together to define optimal biomarkers and endpoints in AMD.
According to a news release from the company, RIMR members from around the world will now be able to connect through RetinAI’s cloud-based platform, RetinAI Discovery, to facilitate a frictionless collaboration and derive insights on global AMD datasets, helping to advance research in this disease that is a leading cause of blindness in older individuals.1
A global concern for vision health, AMD affects about 170 million people, making it the third leading cause of vision loss worldwide. In the United States alone, the prevalence of AMD is on a level with all of the invasive cancers combined, driving an increase in healthcare costs. The company noted in its news release the disease burden varies by region, as illustrated by studies showing differences in AMD prevalence between Western countries and China, and among ethnic groups globally.
By joining the RIMR consortium, RetinAI will be able to leverage its innovative digital health technologies as a technology backbone to support RIMR’s international network of leading experts in AMD to aggregate and analyze, at-scale, research and real-world clinical and imaging data. The result will be the generation of a highly diverse database and analysis using AI to help address leading research questions of AMD, such as differences among ethnic groups.1
Carlos Ciller, PhD, CEO of RetinAI, noted in the news release that by joining RIMR, the company is setting the foundation to connect leading AMD experts from around the world to help advance their important biomarker-led research.
“We are thrilled to be a part of the consortium and help to facilitate cutting-edge research with a shared goal of improving patient care” he added.
SriniVas Sadda, MD, executive committee chairman for RIMR, Director of the AI Laboratory at Doheny Eye Institute, and professor, David Geffen School of Medicine at UCLA, said the organization is excited about working with RetinAI as a member of the consortium.
“RetinAI’s focus on digital health technologies and connectivity in Ophthalmology will enable us to build a highly-diverse database in AMD, providing the enriched insights to advance our understanding of AMD to drive our goal for finding a cure in AMD,” Sadda concluded in the news release.